Predictors of response in treatment-resistant schizophrenia – a meta-analysis

2019 ◽  
Vol 29 ◽  
pp. S121
Author(s):  
A. Seppälä ◽  
J. Pylvänäinen ◽  
J. Miettunen ◽  
M. Isohanni ◽  
I. Corripio ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Treatment Resistant ◽  
Predictors Of Response

ECT in schizophrenia: a review of the evidence

2018 ◽  
Vol 31 (03) ◽  
pp. 115-127 ◽  
Author(s):  
Sandeep Grover ◽  
Swapnajeet Sahoo ◽  
Anjumoni Rabha ◽  
Raman Koirala
Keyword(s):  
Effective Treatment ◽  
Electroconvulsive Therapy ◽  
Suicidal Behaviour ◽  
Treatment Guidelines ◽  
Meta Analysis ◽  
Treatment Resistance ◽  
First Episode ◽  
Treatment Resistant ◽  
Predictors Of Response ◽  
First Episode Schizophrenia

AbstractElectroconvulsive therapy (ECT) was initially used for the treatment of schizophrenia, but over the years with the advent of antipsychotics, its use in schizophrenia has been limited. Treatment guidelines vary in their recommendations for the use of ECT in schizophrenia. The usual indications of its use among patients with schizophrenia include treatment resistance, to augment pharmacotherapy, to manage catatonia, suicidal behaviour, severe agitation and clozapine-resistant schizophrenia. Available literature, including meta-analysis and systematic reviews, suggest that ECT is a safe and effective treatment in patients with schizophrenia. However, despite the available evidence, it is highly underutilised and is often used as one of the last resort among patients with schizophrenia. This review focuses on the indications of use of ECT in schizophrenia, studies evaluating its effectiveness, efficacy in certain special situations like first episode schizophrenia, adolescents, catatonia etc., predictors of response to ECT in schizophrenia and influence of various ECT-related parameters on efficacy/effectiveness among patients with schizophrenia. From the review, it can be concluded that ECT is not only is beneficial as an augmenting strategy in treatment-resistant schizophrenia but also can be used effectively in patients with schizophrenia in various other situations.

scholarly journals Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis

2021 ◽  
Vol 236 ◽  
pp. 123-134
Author(s):  
Annika Seppälä ◽  
Jenni Pylvänäinen ◽  
Heli Lehtiniemi ◽  
Noora Hirvonen ◽  
Iluminada Corripio ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Pharmacological Treatments ◽  
Treatment Resistant ◽  
Predictors Of Response

scholarly journals Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension – Results of a Systematic Review and Meta-Analysis

2014 ◽  
Vol 17 (7) ◽  
pp. A757-A758 ◽  
Author(s):  
M. McBride ◽  
H. Krum ◽  
M. Schlaich ◽  
R. Whitbourn ◽  
T. Walton ◽  
...  
Keyword(s):  
Systematic Review ◽  
Resistant Hypertension ◽  
Renal Denervation ◽  
Meta Analysis ◽  
Treatment Resistant

scholarly journals Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis – CORRIGENDUM

2018 ◽  
Vol 214 (5) ◽  
pp. 308-308
Author(s):  
Rebecca Strawbridge ◽  
Ben Carter ◽  
Lindsey Marwood ◽  
Borwin Bandelow ◽  
Dimosthenis Tsapekos ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

scholarly journals Placebo response in treatment resistant depression: a systematic review and meta-analysis of multiple treatment modalities

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S261-S262
Author(s):  
Brett D M Jones ◽  
Cory R. Weissman ◽  
Jewel Karbi ◽  
Tya Vine ◽  
Louise S. Mulsant ◽  
...  
Keyword(s):  
Systematic Review ◽  
Brain Stimulation ◽  
Placebo Effect ◽  
Meta Analysis ◽  
Specific Treatment ◽  
Placebo Response ◽  
Treatment Modalities ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

AimsThe placebo response in depression clinical trials is a major contributing factor for failure to establish the efficacy of novel and repurposed treatments. However, it is not clear as to what the placebo response in treatment-resistant depression (TRD) patients is or whether it differs across treatment modalities. Our objective was to conduct a systematic review and meta-analysis of the magnitude of the placebo response in TRD patients across different treatment modalities and its possible moderators.MethodSearches were conducted on MEDLINE and PsychInfo from inception to January 24, 2020. Only studies that recruited TRD patients and randomization to a placebo (or sham) arm in a pharmacotherapy, brain stimulation, or psychotherapy study were included (PROSPERO 2020 CRD42020190465). The primary outcome was the Hedges’ g for the reported depression scale using a random-effects model. Secondary outcomes included moderators assessed via meta-regression and response and remission rate. Heterogeneity was evaluated using the Egger's Test and a funnel plot. Cochrane Risk of Bias Tool was used to estimate risks.Result46 studies met our inclusion criteria involving a total of 3083 participants (mean (SD) age: 45.7 (6.2); female: 52.4%). The pooled placebo effect for all modalities was large (N = 3083, g = 1.08 ,95% CI [0.95-1.20)I 2 = 0.1). The placebo effect in studies of specific treatment modalities did not significantly differ: oral medications g = 1.14 (95%CI:0.99-1.29); parenteral medications g = 1.32 (95%CI:0.59-2.04); ayahuasca g = 0.47 (95%CI:-0.28-1.17); rTMS g = 0.93 (95%CI:0.63-1.23); tDCS g = 1.32 (95%CI:0.52-2.11); invasive brain stimulation g = 1.06 (95%CI:0.64-1.47). There were no psychotherapy trials that met our eligibility criteria. Similarly, response and remission rates were comparable across modalities. Heterogeneity was large. Two variables predicted a lager placebo effect: open-label prospective design (B:0.32, 95%CI: 0.05-0.58; p:0.02) and sponsoring by a pharmaceutical or medical device company (B:0.39, 95%CI:0.13-0.65, p:0.004)). No risk of publication bias was found.ConclusionThe overall placebo effect in TRD studies was large (g = 1.08) and did not differ among treatment modalities. A better understanding of the placebo response in TRD will require: standardizing the definition of TRD, head-to-head comparisons of treatment modalities, an assessment of patient expectations and experiences, and standardized reporting of outcomes.

Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis

2020 ◽  
Vol 32 (5-6) ◽  
pp. 477-490 ◽  
Author(s):  
Ben Carter ◽  
Rebecca Strawbridge ◽  
Muhammad Ishrat Husain ◽  
Brett D. M. Jones ◽  
Roxanna Short ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Relative Effectiveness ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression
Sign in / Sign up

Export Citation Format

Share Document